Do the Washington Panel recommendations hold for europe inversigating the relation between quality of life versus work-status, absenteeism and presenteeism by Knies, S. (Saskia) et al.
Knies et al. Cost Effectiveness and Resource Allocation 2014, 12:24
http://www.resource-allocation.com/content/12/1/24RESEARCH Open AccessDo the Washington Panel recommendations hold
for Europe: investigating the relation between
quality of life versus work-status, absenteeism
and presenteeism
Saskia Knies1,2,3*, Annelies Boonen4 and Johan L Severens3,5Abstract
Background: The question of how to value lost productivity in economic evaluations has been subject of debate
in the past twenty years. According to the Washington panel, lost productivity influences health-related quality of
life and should thus be considered a health effect instead of a cost to avoid double counting. Current empirical
evidence on the inclusion of income loss when valuing health states is not decisive. We examined the relationship
between three aspects of lost productivity (work-status, absenteeism and presenteeism) and patient or social
valuation of health-related quality of life (HRQoL).
Methods: Cross-sectional survey data were collected from a total of 830 respondents with a rheumatic disorder
from four West-European countries. Health-related quality of life was expressed in either the European societal utility
using EQ-5D-3L or the patient valuation using EQ-VAS. The impact of work-status (four categories), absenteeism
(absent from paid work during the past three months), and presenteeism (QQ method) on EQ-5D utilities and VAS
scores was examined in linear regression analyses taking into account demographic characteristics and disease
severity (duration, pain and restriction).
Results: The relationship between work-status, absenteeism or presenteeism and HRQoL was stronger for patient
valuation than societal valuation. Compared to work-status and presenteeism the relationship between absenteeism
and HRQoL was even less explicit. However, results for all measures of lost productivity are only marginally significant
and negligible compared to the influence of disease-related restrictions.
Conclusions: This survey study in patients with a rheumatic disorder in four European countries, does not fully support
the Washington panel’s claim that lost productivity is a significantly related with HRQoL, and this is even more apparent
for absenteeism than for work-status and presenteeism. For West-European countries, there is no reason, to include
absenteeism in the QALY. Findings need to be confirmed in other disease areas.
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A growing number of jurisdictions require economic
evaluations for decisions about reimbursement of new
technologies, particularly pharmaceuticals. For this reason,
several jurisdictions have developed guidelines for pharma-
coeconomic evaluations, outlining how to submit official
reimbursement applications. However, these recommenda-
tions vary widely [1,2]. One of the main aspects influencing
the outcome of an economic evaluation is the recom-
mended perspective, as this largely determines the costs
and effects to be included [3,4].
In relation to the discussion on the perspective, the
way to include the patient’s lost productivity in eco-
nomic evaluations is being debated [5]. When accepting
the societal perspective, the next question is the ap-
proach in how to include lost productivity, as costs
(nominator) or as effect (denominator) [4-6]? The main
advocate of incorporating lost productivity of the patient
in the effect side is the Washington Panel [7], whereas
other researchers’ have made a plea for the cost side [4].
Thus, all in all there is no consensus on how to value
lost productivity in costs. Still most national pharmacoe-
conomic guidelines containing recommendations on in-
clusion of lost productivity adhere to the cost side [8].
Nevertheless, the discussion on the valuation of lost
productivity and the relation between health-related
quality of life and productivity is still continuing. So far,
however, research in this field is scarce and concentrates
on the issue whether people take personal loss of income
or lost production for society into account when valuing
health states [9].
The Washington Panel distinguishes five components
of lost productivity, two of which should be included in
the QALY or denominator, namely I) the effects of lost
productivity on the sick employee and II) the effects of
lost leisure time on the sick employee. In contrast, III)
the effect on the employer (recruitment and training of
new employee) and IV) the external effects should be
valued at the cost side or in the numerator. Lastly, V)
the costs related to mortality on lost productivity should
be presented separately and should not be included in
the cost-effectiveness ratio as the denominator already
contains the effects of mortality when the QALY is the
measure of effectiveness [4,7]. According to the Wash-
ington Panel lost productivity influences a patient’s
health-related quality of life and thus can be considered
a health effect, which implies that the full impact of
morbidity should be included in the denominator [7]. As
the denominator of the cost-effectiveness ratio captures
the full value of health effects, inclusion of lost product-
ivity in the numerator will result in double-counting of
lost productivity [10]. Still, this will only be the case
when the QALY is used as a measure of benefit [7]. It
can be difficult for both the patient and the generalpublic, however, to comprehend that the impact of the
disease on work should be taken into account when
valuing health states, and furthermore to distinguish be-
tween the impact of illness on lost productivity for soci-
ety and the impact of the illness on the role function as
a worker for the individual employee [7]. Moreover,
costs might be underestimated by considering net wages
rather than gross wages as a proxy for productivity
[11,12]. In addition, when valuing health, there is not
always a link between reduced productivity and loss of
income or at least not a proportional loss of income due
to receiving social benefits to compensate for the sick
employee’s reduction of salary [4,11]. In relation to this,
it is noteworthy that the profiles of health do not
describe the impact of disease on work or income. This
is especially a problem when someone from the general
public is valuing a health state. However, the Washing-
ton Panel indicates that the preference weights to calcu-
late the utilities from health states should be based on
community or societal preferences instead of patient or
provider preferences. It is argued that a representative
sample of fully informed members of the community
will, according to the Washington Panel, give the best
representation of society’s preferences for particular
health states [7,10]. Last but not least, the Washington
Panel does not explain clearly whether presenteeism as a
type of lost productivity should be valued as a kind of
costs or effect.
To our knowledge, so for it has not yet been investi-
gated to what extent aspects of lost productivity such as
being work disabled, being on sick leave and having
presenteeism, influence the assessment of the quality of
life of people with chronic health problems. The aim of
our study is to examine the relationship between three
aspects of lost productivity (work-status, absenteeism
and presenteeism) and direct patient or indirect societal
perspective of health-related quality of life (HRQoL). A
population of persons with rheumatic disorders was
chosen as the case sample, since in rheumatic disorders
the influence of disease on productivity is high and
therefore relationships are easier to study.
Methods
Population and questionnaire
Data were collected in March 2010 using an online ques-
tionnaire in four West-European countries, namely the
Netherlands, the United Kingdom, France and Germany.
The data were collected within the framework of another
study, on between-country differences in the self-reported
lost productivity of people with a rheumatic disorder. The
data collection was carried out by the research organization
TNS NIPO and all respondents were voluntary members
of their patient panels of people with a rheumatic dis-
order. Eligible members of these panels received an
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Persons were considered to be eligible if they them-
selves had stated to have a rheumatic disorder and were
between twenty and seventy years of age. Although at
the time of the study the retirement age in all countries
was sixty-five or younger, people up to seventy years of
age could participate if they were still working or wish-
ing to have paid employment. A total of two hundred
respondents per country with a rheumatic disorder were
included. Overall, eight hundred-thirty respondents
filled out the questionnaire as two hundred-thirty re-
spondents in the Netherlands filled out the question-
naire. More details about the procedure and selection of
respondents have been reported elsewhere [13].
This cross-sectional survey was carried out in compe-
tent subjects without any intervention. The study did
not involve any form of randomization, testing medical
treatments or obtaining humans material or invasion of
the study participant’s integrity. According to the Dutch
Medical Research Involving Human Subjects Acts (see
www.ccmo.nl) approval by a medical-ethics committee is
waived for such studies. This holds true for the three
other countries as well, and therefore no approval of
ethics committees in any of the four study countries was
needed. Furthermore, participation was voluntary. The
collected survey data and results were non-traceable to
individual respondents.
The questionnaire used in the survey was composed of a
number of validated self-report questionnaires. Health-
related quality of life was measured using the EuroQol-
5D-3L (EQ-5D) including the Visual Analogue Scale
(VAS) [14]. Demographic (age, gender, work-status), work
characteristics and lost productivity (both absenteeism and
presenteeism) were measured using the Productivity and
Disease Questionnaire (PRODISQ), which is a modular
questionnaire developed to measure lost productivity in
paid labour [15,16]. Several questions were added to assess
absenteeism, including having been absent in the last three
months, currently absent and the number of days absent
in the last three months. Presenteeism in PRODISQ is
assessed using the QQ approach, by which respondents in-
dicate how well (quality) and how much (quantity) work
they carried out on their last working day on a ten point
scale (10 indicating normal quality and quantity). An over-
all presenteeism score was created from both presenteeism
scales [15,16]. Questions about severity of the rheumatic
disorder were selected from the Dutch-Arthritis Impact
Measurement Scales-2 (Dutch-AIMS2), an instrument to
assess the health status of people with a rheumatic
disorder. As part of the AIMS, respondents were asked to
indicate the level of experienced restrictions due to their
rheumatic disorder in the last six months on a three point
scale (not restricted, somewhat restricted and seriously re-
stricted) and to rate pain due to the rheumatic disorder ona scale from 0 to 100 (no pain to severe pain). In addition,
the respondents were asked to state when they received
the diagnosis of their rheumatic disorder [17].
Respondents filled out the online questionnaire in the
language of the specific country, for example respon-
dents in Germany received the German-language ques-
tionnaire. Validated translations of questionnaires were
utilized when available in the relevant language (EQ-5D-
3L, AIMS). For questions and questionnaires for which
no validated translation was available (demographics and
PRODISQ), a translation from Dutch to language of
interest by professional translators was provided [13].
Statistical analyses
Prior to analysis, some variables were redefined or calcu-
lated. The utilities of the EQ-5D-3L health states were
calculated using the European value set derived from an
experiment respondents from the general population in
six European countries [14], generally overlapping with
the countries in our survey. Work-status of the respon-
dents was classified categorised into four categories: I)
having a paid job; II) having a paid job, but currently ab-
sent due to illness; III) no paid job, but receiving disability
benefit; and IV) unemployed and not receiving disability
benefit. All variables were checked for missing or abnor-
mal values and for distribution by plotting residuals and
inspecting if the data fulfilled the assumptions of normal-
ity. Missing data were found by the variables ‘currently ab-
sent’ and ‘number of days absent in the last three months’.
All missing data could be imputed using the answer on
the variable ‘having been absent in the last three months’,
since no data were missing for the latter variable.
The demographic, disease and work characteristics of
the sample are presented using descriptive statistics for
the total group and sub-groups defined by work-status
and were compared across groups using one-way ANOVA
for the continuous independent variables and χ2- tests for
the categorical variables. Linear regression analyses were
performed in several models to examine the influence of I)
work-status, II) absenteeism, III) presenteeism and IV)
absenteeism and presenteeism together on either direct
patients’ VAS-score or EQ-5D utility score, which reflects
the societal preference. Possible explanatory variables were
checked on normality, colinearity between covariates
was explored as well as linearity between covariates and
quality of life data (both VAS as well as EQ-5D data). All
remaining variables were included as possible confounders
or independent factors in the models.
Results
Characteristics of the respondents
Table 1 lists the characteristics of the whole sample (830
respondents) and of the different work-status categories.
The largest group (57.6%) is the group with a paid job
Table 1 Characteristics of the respondents (n = 830)
Total population Working, not reporting
abenteeism1
Working, currently
absenteeism2
Not working, getting
disability benefit3
Not working,
unemployed4
Number (%) 830 478 (57.6%) 61 (7.3%) 114 (13.7%) 177 (21.3%)
Male (%) 295 (35.5%) 182 (38.1%) 24 (39.3%) 38 (33.3%) 51 (28.8%)
Age (range) 49 (20-70) 47 (20-65)3,4*** 46 (23-63)3**, 4*** 51(25-64)1***, 2** 52 (24-70)1,2***
EQ-5D (European) (range -0.074-1) 0.743 (0.05-1.00) 0.794 (0.21-1.00)2,3,4*** 0.685 (0.05-1.00)1***,3* 0.600 (0.05-1.00)1,4***,2* 0.717 (0.05-1.00)1,3***
VAS EQ-5D (range 0 -100) 63.64 (0-100) 69.16 (0-100)2,3,4*** 56.34 (2-100)1*** 49.93 (7-95)1,4*** 60.05 (0-98)1,4***
Pain (range 0 -100) 43.30 (0-100) 39.07 (0-100)2,4*,3*** 48.57 (0-95)1* 55.18 (2-100)1***,4* 45.23 (0-100)1,3*
Disease duration (range) 12.61 (0-56) 11.73 (0-55)3**,4* 10.67 (1-36)3* 15.25 (1-52)1**,2* 13.95 (1-56)1*
Seriously restricted (%) 155 (18.7%) 44 (9.2%)2,3***,4** 25 (41%)1,4*** 51 (44.7%)1,4*** 35 (19.8%)1**,2,3***
Somewhat restricted (%) 530 (63.9%) 320 (66.9%)3* 34 (55.7%) 60 (52.6%)1* 116 (65.5%)
Country of residence
the Netherlands (%) 230 (27.7%) 156 (32.6%) 17 (27.9%) 32 (28.1%) 25 (14.1%)
United Kingdom (%) 200 (24.1%) 105 (22%) 111 (18%) 36 (31.6%) 48 (27.1%)
France (%) 200 (24.1%) 114 (23.8%) 15 (24.6%) 23 (20.2%) 48 (27.1%)
Germany (%) 200 (24.1%) 103 (21.5%) 18 (29.5%) 23 (20.2%) 56 (31.6%)
Not working due to RD (%) 160 (9.3%) NA NA 103 (90.4%) 57 (32.2%)
Having been absent in the last
3 months (%)
167 (20.1%) 106 (22.2%)2*** 61 (100%)1*** NA NA
Number of days absent (range 0-92) 18.89 (0-92) 8.58 (0-92)2*** 36.80 (1-91)1*** NA NA
Presenteeism – quantity (range 0-10) 8.60 (0-10) 8.81 (0-10)2*** 7.02 (0-10)1*** NA NA
Presenteeism – quality (range 0-10) 8.83 (0-10) 8.94 (0-10)2*** 8.03 (0-10)1*** NA NA
Overall presenteeism – quantity *
quality (range 0-100)
78.80 (0-100) 80.91 (0-100)2*** 62.30 (0-100)1*** NA NA
1all respondents with a paid job who are when filling out questionnaire not absent.
2all respondents with a paid job who are when filling out questionnaire absent.
3all respondents without a paid job who receive disability benefit.
4all respondents without a paid job who do not receive disability benefit.
NA: not applicable.
RD: rheumatic disorder.
*p <0.10; **p <0.01; ***p <0.001.
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ity benefit; 13.7% were receiving disability benefit; and
7.3% reported being absent.
Respondents who had a paid job but were currently ab-
sent from work tended to be more frequently males, youn-
ger, living in the Netherlands and to have a shorter disease
duration. Those who were not absent had less pain, were
less often seriously restricted and had better quality of life
based on both VAS and EQ-5D. In addition, they reported
a lower average number of days absent in the last three
months than the respondents who were absent, and higher
presenteeism scores on their last working day, which im-
plies that they were close to fully productive. However, be-
cause respondents answered these questions on their last
working day, there is a risk of recall bias for respondents
who are absent for a longer period of time. Respondents
who receive disability benefit had the lowest quality of
life, both measured with the VAS and EQ-5D. Further-
more, they had more pain, were more frequently seriouslyrestricted, more often living in the Netherlands or in the
United Kingdom and had a longer disease duration. The
unemployed respondents were clearly the oldest, more
often females and living in Germany. However, they were
less often seriously restricted than respondents on sick
leave, but they had longer disease duration. About one
third of them indicated they did not work due to their
rheumatic disorder.
Relation between quality of life and work-status
Table 2 presents the results of the linear regression ana-
lyses that explored the influence of work-status on both
the VAS scores (self-reported health) and the EQ-5D de-
rived utilities. The model for the VAS scores has an R2 of
0.308, which implies that 30.8% of the variance of the VAS
scores are explained by the model. The R2 of the model
for the EQ-5D utilities was 0.354 (explaining 35.4%).
The variables age, pain due to rheumatic disorder, years
of rheumatic disorder, restriction due to disease and work-
Table 2 Linear regression exploring the impact of work-status on VAS scores and EQ-5D utilities (n = 830)
VAS scores (self-reported health) Utilities European EQ-5D value set
B Std. error Beta B Std. error Beta
Work status
Absent versus working -3.882 2.524 -.047 -.027 .021 -.037
Disabled versus working -9.504 2.021 -.152*** -.101 .017 -.186***
Unemployed versus working -6.118 1.640 -.117*** -.050 .014 -.109***
Age (years) .104 .065 .049 .001 .001 .062*
Gender (1: male, 2: female) 1.501 1.326 .033 .012 .011 .031
Pain (range 0-100) -.026 .024 -.034 -.001 .000 -.168***
Disease duration (years) -.111 .064 -.052* -.001 .001 -.033
Restriction due to disease
Seriously restricted versus not restricted -32.649 2.346 -.592*** -.247 .020 -.514***
Somewhat restricted versus not restricted -15.443 1.780 -.345*** -.071 .015 -.184***
Note: R-square .308 Note: R-square .354
*p <0.10; **p <0.01; ***p <0.001.
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Including the same covariates, respondents with sickness
absence scored (Beta) -0.047 worse on VAS and -0.037 on
EQ-5D compared to respondents with a paid job after
correcting for other variables. Respondents who receive
disability benefit are expected to score -0.152 worse on
VAS and -0.186 points on EQ-5D compared to the cur-
rently working respondents. Unemployed respondents
scored -0.117 worse on VAS and -0.109 on EQ-5D com-
pared to the working respondents. Seriously restricted
respondents had the lowest quality of life both on the VAS
and EQ-5D. For both models it was checked whether
the inclusion of work-status had a significant influence.
For the VAS model the F-change was (3, 820) =9.47,
p <0.0001. The F-change for the EQ-5D European model
was (3, 820) =3.11, p <0.0001.Table 3 Linear regression on influence of absenteeism restric
VAS score
B S
Absenteeism
Currently absent versus not absent at all -4.365 2
Absent in last three months versus not absent at all -2.123 1
Age (years) .038 .
Gender (1: male, 2: female) .242 1
Pain (range 0-100) -.081 .
Disease duration (years) -.126 .
Restriction due to disease
Seriously restricted versus not restricted -30.595 2
Somewhat restricted versus not restricted -13.323 2
Note: R-square
*p <0.10; **p <0.01; ***p <0.001.Quality of life and absenteeism
Table 3 shows the results of the linear regression on the
relation between the quality of life and absenteeism for
all respondents with paid work (n =537). The influence
of absenteeism (currently absent or absent in the last
three months but not now versus not absent in the last
three months) was explored while correcting for other
possible influential variables. The R2 of the model
explaining the VAS score was 0.263 and the R2 of the
model explaining EQ-5D utilities was 0.310. While age
and duration of the rheumatic disorder had no statisti-
cally significant influence on quality of life, pain and
restrictions were major determinants for both patient
reported VAS health and indirect societal value for
health. Not having been absent in the last three months
resulted in a significantly higher quality of life comparedted to respondents with paid employment (n = 537)
(self-reported health) Utilities European EQ-5D value set
td. error Beta B Std. error Beta
.595 -.068* -.032 .020 -.061
.975 -.041 -.017 .015 -.041
081 .018 .000 .001 .010
.581 .006 .021 .012 .061*
029 -.112** -.001 .000 -.223***
086 -.056 -.001 .001 -.034
.978 -.502*** -.238 .023 -.485***
.013 -.311*** -.064 .016 -.185***
.263 Note: R-square .310
Table 4 Linear regression on influence of presenteeism restricted to respondents with paid employment (n = 537)
VAS score (self-reported health) Utilities European EQ-5D value set
B Std. error Beta B Std. error Beta
Overall presenteeism (range 0-100) .137 .028 .183*** .001 .000 .128**
Age (years) .026 .079 .012 .000 .001 .008
Gender (1: male, 2: female) -.083 1.552 -.002 .019 .012 .056
Pain (range 0-100) -.075 .029 -.103** -.001 .000 -.218***
Disease duration (years) -.160 .085 -.071* -.001 .001 -.045
Restriction due to disease
Seriously restricted versus not restricted -29.971 2.811 -.492*** -.237 .022 -.484***
Somewhat restricted versus not restricted -13.065 1.962 -.305*** -.063 .015 -.183***
Note: R-square .290 Note: R-square .322
*p <0.10; **p <0.01; ***p <0.001.
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0.068 point.Quality of life and presenteeism
Table 4 shows the results of the linear regression in
which the correlation between presenteeism (product of
quality and quantity) and quality of life was explored for
persons with paid work, including those currently
absent, correcting for possible influential variables. The
R2 of the model explaining the VAS scores was 0.290
and the R2 of the model explaining EQ-5D utilities was
0.322. While age and gender had no independent influ-
ence on quality of life, disease duration contributed to
the variation in patient reported VAS health, and pain
and restrictions were major determinants for both
patient reported VAS health and indirect societal value
for health. Each point of improvement on overallTable 5 Linear regression on influence of absenteeism and pr
employment (n = 537)
VAS score
B S
Absenteeism
Currently absent versus not absent at all -2.321 2
Absent in last three months versus not absent at all -1.529 1
Overall presenteeism (range 0-100) .132 .
Age (years) .017 .
Gender (1: male, 2: female) -.084 1
Pain (range 0-100) -.075 .
Disease duration (years) -.159 .
Restriction due to disease
Seriously restricted versus not restricted -29.124 2
Somewhat restricted versus not restricted -12.806 1
Note: R-square
*p <0.10; **p <0.01; ***p <0.001.presenteeism increased VAS by 0.183 point and EQ-5D
by 0.128 point.Quality of life and absenteeism and presenteeism
Table 5 shows the results of the linear regression ex-
ploring the influence of absenteeism and overall pres-
enteeism (product of quality and quantity) on quality of
life in persons with paid work (including those cur-
rently absent), correcting for possible influential vari-
ables. The R2 of the model explaining the VAS scores
was 0.291 and the R2 of the model explaining EQ-5D
utilities was 0.324.
While age, gender and absenteeism had no independ-
ent influence on quality of life, disease duration contrib-
uted to the variation in patient reported VAS health.
However, pain due to the rheumatic disorder and restric-
tions were major determinants for both patient reportedesenteeism restricted to respondents with paid
(self-reported health) Utilities European EQ-5D value set
td. error Beta B Std. error Beta
.585 -.036 -.020 .020 -.040
.942 -.030 -.014 .015 -.033
029 .176*** .001 .000 .120***
079 .008 5.02 *10-5 .001 .003
.554 -.002 .019 .012 .056
029 -.103** -.001 .000 -.217***
085 -.070* -.001 .001 -.044
.939 -.478*** -.230 .023 -.468***
.978 -.299*** -.061 .016 -.176***
.291 Note: R-square .324
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point of improvement on overall presenteeism increased
VAS by 0.176 point and EQ-5D by 0.120 point.
Discussion
The question whether the approach recommended by the
Washington Panel is justified cannot be answered with a
simple yes or no. The results of this study show that the
situation is more complex. First, although the relations
between work-status and presenteeism on the one hand
and health-related quality of life on the other hand (both
patient and societal valuation) are significant, the relation-
ship between absenteeism and health-related quality of life
is less clear. Secondly, while there is a significant relation-
ship between patient reported health-related quality of
life and work-status, the relation between the societal
valuation and absenteeism is not significant. Furthermore,
when presenteeism and absenteeism are both included in
the analyses, the influence of absenteeism is no longer sig-
nificant. Since the Washington Panel recommends using
societal preferences when calculating the QALY, the mon-
etary valuation of absenteeism will probably not result
in double counting as the Washington Panel advocates.
Disease related restrictions seem to affect quality of life
the most, especially for seriously restricted respondents. In
addition, also pain due to the rheumatic disorder is signifi-
cantly correlated with quality of life.
Comparison with the literature
In previous research the relation between health-related
quality of life and lost productivity was investigated by
either looking whether respondents take into account
the income effects of lost productivity when valuing
health states, or whether respondents value health states
differently when they are explicitly asked to take into
account lost productivity or income effects due to lost
productivity. Our results are generally in line with the
conclusions from these previous studies. Based on a
review by Tilling et al. [18] concluded that the empirical
evidence on this issue is not decisive as the existing
studies show a number of inconsistencies on whether or
not the general population and patients spontaneously
include income effects when valuing health states. Shiroiwa
et al. [19] investigated the influence of income reduction on
utility scores by asking respondents from the Japanese
general population to value EQ-5D health states whereby
respondents were given different instructions on whether
or not to consider income reduction [19]. The maximum
difference between the different types of instructions in the
valuation of the health states was estimated to be 0.05.
Therefore the authors concluded that the impact of
double counting is negligible, seeing that the effect of
income on utility scores does not only reflect wage
loss [19]. Krol et al. [20] tried to predict patient’sproductivity from health states by asking a sample of
the Dutch general population to estimate the expected
level of productivity for several EQ-5D health states. A
linear relationship between utility score and productiv-
ity was not found as different levels of the EQ-5D had a
different impact on quality of life than on productivity. Es-
pecially lost productivity due to presenteeism was overes-
timated in their prediction model. Thus, previous research
shows that the relationship between quality of life, income
loss and lost productivity is not clear-cut, which is in
accordance with our results.
As far as we know, our study was the first to look sim-
ultaneously at the relationship between three different
components of lost productivity: work-status, absentee-
ism and presenteeism, and the combination of absentee-
ism and presenteeism. Earlier studies did not take into
account disease-specific characteristics that could influ-
ence the health-related quality of life, such as disease
duration, pain and restriction due to disease, when in-
vestigating the relationship between quality of life and
lost productivity. By including these covariates into the
analyses the influence of lost productivity is not biased
by disease specific characteristics.
If the findings of our study should prove to be
generalizable to other disease areas or to the general popu-
lation, then the recommendations in the national pharma-
coeconomic guidelines regarding the valuation of lost
productivity need not be changed. As mentioned before
most national pharmacoeconomic guidelines recommend
valuing lost productivity as costs. This is especially true for
recommendations about the valuation of absenteeism [8].
In the present study the relationship between absenteeism
and the societal valuation of health-related quality of life
was not statistically significant and the relationship with
the patient valuation had a small significant effect.
Limitations of the study
Several limitations of this study should be addressed
related to both the study sample and the explorative
nature of the study. First, we included only respondents
with a self-reported rheumatic disorder to create a sample
with a relatively homogeneous disease state in lost prod-
uctivity is often encountered. Findings for other diseases
and patient populations could well be different; therefore
the generalizability to other disease areas or to the general
population might be limited. Secondly, distribution of the
eight hundred-thirty respondents over the four work-
status groups was unequal, with the largest number of re-
spondents in the group of having a paid job, not reporting
absenteeism. Still, this total number of respondents was
large enough to statistically significant differences. How-
ever, the numbers of respondents per group were too low
to perform analyses for each country separately. Third, due
to the limited number of explanatory variables in the survey
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might affect the relation between the different types of lost
productivity and quality of life [19], such as job and work-
place related factors, but also additional disease characteris-
tics or personal factors such as coping or self-management
styles [13]. This is especially true for presenteeism. Still
about 30% of the health-related quality of life could be ex-
plained by the statistical models. This study indicates that
additional research is needed to better understand the rela-
tionship between presenteeism and quality of life. Fourth,
in our study we only had cross-sectional data and therefore
it was not possible to explore possible relations between
quality of life and lost productivity over time.
Conclusion
The recommendations of the Washington Panel to in-
clude lost productivity due to sick leave in the denomin-
ator have stimulated research projects investigating the
relationship between quality of life and absenteeism.
However, limited research has been carried out on the
influence of presenteeism on quality of life, seeing that
presenteeism can result in lost productivity. Therefore,
additional research is needed to better understand the
relationship between presenteeism and quality of life.
This study showed that especially being absent has
marginal influence on quality of life. As a consequence,
results provide further support for including absenteeism
in the costs side in economic evaluations as this will not
lead to double-counting of lost productivity. As work-
status and presenteeism seem to have at least some
influence on quality of life, the extent towards these
aspects should or should not be included in the costs
remains more open. So for the time being, it can be
concluded that the Washington Panel recommendations
on lost productivity do not seem to hold for Europe.
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